WilmerHale Reps Editas Medicine in Licensing of New Technologies

WilmerHale Reps Editas Medicine in Licensing of New Technologies

Firm News

Related Solutions

We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Editas Medicine, Inc., a leading genome editing company, announced it has exclusively licensed intellectual property related to new CRISPR technologies for human therapeutics that will enhance and broaden the range of medicines the company can develop. These global licensing agreements include intellectual property owned by the Broad Institute of MIT and Harvard (Broad Institute), Harvard University, Massachusetts Institute of Technology (MIT), Wageningen University, the University of Iowa, and the University of Tokyo for the new CRISPR genome editing system.
 
The WilmerHale deal team included Partners Steven Barrett and Rosemary Reilly; Counsel Jeffries Oliver-Li, Associates Hilary Baker-Jennings and Brett Bromann; and Attorney Heidi Treiber.
 
Read the press release published by Editas Medicine for more information.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel